Shauna L. Hillman, MS; Aminah Jatoi, MD; Carrie A. Strand, BS; et al.
free access
JAMA Oncol. 2023;9(8):1041-1047. doi:10.1001/jamaoncol.2023.1648
This cohort study reports rates of and baseline factors associated with withdrawal of consent among patients in cancer clinical trials.
-
Editorial
Enhancing Patient Retention in Clinical Trials鈥擲trategies for Success
Dame Idossa, MD; Shruti Patel, MD; Narjust Florez, MD
JAMA Oncol
Jonas Saal, MD; Tobias Bald, PhD; Markus Eckstein, MD; et al.
open access
JAMA Oncol. 2023;9(8):1048-1055. doi:10.1001/jamaoncol.2023.1822
This prognostic study assesses the prognostic and predictive value of the modified Glasgow prognostic score during treatment in patients with metastatic renal cell carcinoma.
-
Editorial
Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma
Georges Gebrael, MD; Gliceida Galarza Fortuna, MD; Neeraj Agarwal, MD
JAMA Oncol
Joël Castelli, MD, PhD; Juliette Thariat, MD, PhD; Karen Benezery, MD; et al.
free access
JAMA Oncol. 2023;9(8):1056-1064. doi:10.1001/jamaoncol.2023.1352
This phase 3 randomized clinical trial conducted in France investigates whether systemic weekly radiotherapy replanning compared with standard intensity-modulated radiotherapy decreases xerostomia in adult patients with squamous cell oropharyngeal cancer.
Roshan S. Prabhu, MD, MS; Tobi Akinyelu, BS; Zachary K. Vaslow, MD; et al.
free access
JAMA Oncol. 2023;9(8):1066-1073. doi:10.1001/jamaoncol.2023.1629
This cohort study examines preoperative stereotactic radiosurgery outcomes and prognostic factors for patients with resected brain metastases.
Lova Sun, MD, MSCE; Benjamin Bleiberg, MD; Wei-Ting Hwang, PhD; et al.
free access
JAMA Oncol. 2023;9(8):1075-1082. doi:10.1001/jamaoncol.2023.1891
This cohort study of advanced non鈥搒mall cell lung cancer patients assesses practice patterns surrounding immunotherapy discontinuation at 2 years and evaluates the association of duration of therapy with overall survival.
Reshma Jagsi, MD, DPhil; William E. Barlow, PhD; Wendy A. Woodward, MD, PhD; et al.
free access
JAMA Oncol. 2023;9(8):1083-1089. doi:10.1001/jamaoncol.2023.1984
This secondary analysis of a clinical trial investigates how often patients with favorable-risk, node-positive breast cancer receive regional nodal irradiation, incidence and predictors of locoregional recurrence rates, and associations between locoregional therapy and disease-free survival.
Isabella R. Pompa, BA; Anushka Ghosh, BS; Shamik Bhat, BS; et al.
free access
has audio
JAMA Oncol. 2023;9(8):1090-1098. doi:10.1001/jamaoncol.2023.1993
This cross-sectional study uses data from the Centers for Disease Control and Prevention to evaluate trends in cancer mortality in the US Hispanic population overall and by cancer type, age, gender, and region from 1999 to 2020.
-
Podcast:
US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020
Lili Mao, MD; Bin Lian, MD; Caili Li, MD; et al.
free access
JAMA Oncol. 2023;9(8):1099-1107. doi:10.1001/jamaoncol.2023.1363
This nonrandomized clinical trial examines the activity and safety of camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma.